Search Results - "Dudek, A. Z."

Interleukin 2 in cancer therapy by Antony, G K, Dudek, A Z

“…Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With…”
Get more information

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours by Khatri, A, Williams, B W, Fisher, J, Brundage, R C, Gurvich, V J, Lis, L G, Skubitz, K M, Dudek, A Z, Greeno, E W, Kratzke, R A, Lamba, J K, Kirstein, M N

“…Background: Gemcitabine is used for the treatment of several solid tumours and exhibits high inter-individual pharmacokinetic variability. In this study, we…”
Get full text

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity by Stish, B J, Oh, S, Chen, H, Dudek, A Z, Kratzke, R A, Vallera, D A

“…Background: Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy. Methods: To address…”
Get full text

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy by DUDEK, A. Z, BODEMPUDI, V, WELSH, B. W, JASINSKI, P, GRIFFIN, R. J, MILBAUER, L, HEBBEL, R. P

“…Angiogenesis and post-natal vasculogenesis are two processes involved in the formation of new vessels, and both are essential for tumour growth and metastases…”
Get full text

Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates : requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins by GUPTA, P, OEGEMA, T. R, BRAZIL, J. J, DUDEK, A. Z, SLUNGAARD, A, VERFAILLIE, C. M

“…We have shown that stromal O-sulfated heparan sulfate glycosaminoglycans (O-S-GAGs) regulate primitive human hematopoietic progenitor cell (HPC) growth and…”
Get full text

Computational methods in developing quantitative structure-activity relationships (QSAR): a review by Dudek, Arkadiusz Z, Arodz, Tomasz, Gálvez, Jorge

“…Virtual filtering and screening of combinatorial libraries have recently gained attention as methods complementing the high-throughput screening and…”
Get more information

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor by Dudek, A Z, Lesniewski-Kmak, K, Shehadeh, N J, Pandey, O N, Franklin, M, Kratzke, R A, Greeno, E W, Kumar, P

“…Bortezomib inhibits nuclear factor- κ B (NF- κ B). Cetuximab is a chimeric mouse–human antibody targeted against epidermal growth factor receptor (EGFR). We…”
Get full text

Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors by Bodempudi, V, Ohlfest, J R, Terai, K, Zamora, E A, Vogel, R I, Gupta, K, Hebbel, R P, Dudek, A Z

“…Endothelial cells and endothelial cell precursors encoding a therapeutic gene have induced antitumor responses in preclinical models. Culture of peripheral…”
Get full text

Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival by Dudek, Arkadiusz Z., Mahaseth, Hemchandra

“…Tumor angiogenesis is stimulated by a pro-angiogenic shift in both inducers and inhibitors of endothelial growth. To study this shift, we measured serum and…”
Get full text

Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation by Miller, Jeffrey S., Curtsinger, Julie, Berthold, Melinda, Malvey, Kirsten, Bliss, Robin L., Le, Chap T., Fautsch, Susan K., Dudek, Arkadiusz Z., Blazar, Bruce R., Panoskaltsis-Mortari, Angela

“…Relapse is the most common cause of treatment failure for advanced cancer, even those treated with autologous hematopoietic cell transplantation (HCT)…”
Get full text

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study by Saggu, G., Stroopinsky, D., Dudek, A.Z., Olszanski, A.J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodón, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R.J., Berger, A., Sachsenmeier, K., Kasar, S.

Get full text

Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C by Dudek, A Z, Pennell, C A, Decker, T D, Young, T A, Key, N S, Slungaard, A

“…Platelet factor 4 (PF4) is an abundant platelet alpha-granule heparin-binding protein. We have previously shown that PF4 accelerates up to 25-fold the…”
Get full text

1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment by McDermott, D F, Vaishampayan, U, Matrana, M, Rha, S Y, Saavedra, A Zurita, Ho, T, Keam, B, Lee, J-L, Joseph, R, Ali, S, Stadler, W, Haas, N B, Sundararajan, S, Park, S H, Mowat, R, Picus, J, Dudek, A Z, Zakharia, Y, Gan, L, Atkins, M B

“…Abstract Background The CXCR4 chemokine receptor modulates immunosuppressive cell trafficking that can inhibit antitumor immune responses. X4P-001 is a…”
Get full text

BLOOD OUTGROWTH ENDOTHELIAL CELL-BASED DELIVERY OF CANCER GENE THERAPY by Dudek, A Z

“…Angiogenesis and postnatal vasculogenesis are two processes involved in the formation of new vessels, an essential requirement for tumor growth and metastasis…”
Get full text

LARGE MULTTVALENT IMMUNOGEN VACCINE IN PATIENTS WITH METASTATIC MELANOMA by Dudek, A Z

“…Metastatic melanoma is an incurable malignancy with a median survival of 6-8 months. While melanoma is refractory to most chemotherapy drugs, its growth may be…”
Get full text

Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials by Chi, Ming, Dudek, Arkadiusz Z

“…Clinical trials of melanoma vaccines have yielded inconclusive data on whether a positive melanoma-specific immune response predicts treatment benefit. The…”
Get full text

Structurally Specific Heparan Sulfates Support Primitive Human Hematopoiesis by Formation of a Multimolecular Stem Cell Niche by Gupta, Pankaj, Oegema, Theodore R., Brazil, Joseph J., Dudek, Arkadiusz Z., Slungaard, Arne, Verfaillie, Catherine M.

“…Stem cell localization, conservation, and differentiation is believed to occur in niches in the marrow stromal microenvironment. Our recent observation that…”
Get full text

Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma by Powell, S. F., Dudek, A. Z.

“…Abstract only e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma. The purpose of this study was to…”
Get full text

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma by Dham, A., Dudek, A. Z.

“…Abstract only 5106 Background: Sunitinib and sorafenib are two small-molecule tyrosine kinase inhibitors (TKI) that have been shown to have antitumor activity…”
Get full text

Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases by POWELL, Steven, DUDEK, Arkadiusz Z

“…Background: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma. The purpose of this study was to evaluate the…”
Get full text